In:
Pharmacogenomics, Future Medicine Ltd, Vol. 20, No. 4 ( 2019-03), p. 225-240
Kurzfassung:
Aim: We report the prevalence and effect of genetic variability on pharmacokinetic parameters of isoniazid and rifampicin. Materials & methods: Genotypes for SLCO1B1, NAT2, PXR, ABCB1 and UGT1A genes were determined using a TaqMan ® Genotyping OpenArray™. Nonlinear mixed-effects models were used to describe drug pharmacokinetics. Results: Among 172 patients, 18, 43 and 34% were classified as rapid, intermediate and slow NAT2 acetylators, respectively. Of the 58 patients contributing drug concentrations, rapid and intermediate acetylators had 2.3- and 1.6-times faster isoniazid clearance than slow acetylators. No association was observed between rifampicin pharmacokinetics and SLCO1B1, ABCB1, UGT1A or PXR genotypes. Conclusion: Clinical relevance of the effects of genetic variation on isoniazid concentrations and low first-line tuberculosis drug exposures observed require further investigation.
Materialart:
Online-Ressource
ISSN:
1462-2416
,
1744-8042
DOI:
10.2217/pgs-2018-0166
Sprache:
Englisch
Verlag:
Future Medicine Ltd
Publikationsdatum:
2019
SSG:
15,3
Permalink